DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2004/0063677 A1 Myhren Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2004/0063677 A1 Myhren Et Al US 2004OO63677A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0063677 A1 Myhren et al. (43) Pub. Date: Apr. 1, 2004 (54) METHODS OF TREATING DSORDERS (30) Foreign Application Priority Data USING LIPOPHILIC DERVATIVES Jan. 24, 1997 (GB)......................................... 97O1441.9 (75) Inventors: Finn Myhren, Porsgrunn (NO); Bernt Borretzen, Heistad (NO); Are Dalen, Trondheim (NO); Marit Liland Publication Classification Sandvold, Porsgrunn (NO) (51) Int. Cl. ............................ A61K 31/573; CO7J 5/00 Correspondence Address: (52) U.S. Cl. ............................................ 514/179; 552/570 JONES DAY 51 Louisiana Aveue, N.W WASHINGTON, DC 20001-2113 (US) (57) ABSTRACT (73) Assignee: Norsk Hydro ASA The properties of biologically active compounds, for (21) Appl. No.: 10/662,441 example drugs and agrochemicals, which contain in their molecular structure one or more functional groupS. Selected (22) Filed: Sep. 16, 2003 from alcohol, ether, phenyl, amino, amido, thiol, carboxylic acid and carboxylic acid ester groups are modified by Related U.S. Application Data replacing one or more of these functional groups by a lipophilic group Selected from those of the formula: (63) Continuation of application No. 10/116,358, filed on RCOO-, RCONH-, RCOS-, RCH-O-, RCH-NH-, Apr. 5, 2002, which is a continuation of application -COOCHR,-CONHCHR and -SCHR, wherein R is No. 09/355,111, filed on Sep. 27, 1999, now aban a lipophilic moiety Selected from cis-8-heptadecenyl, trans doned, filed as 371 of international application No. 8-heptadecenyl, cis-10-nonadecenyl and trans-10-nonadece PCT/NO98/00021, filed on Jan. 23, 1998. nyl. Patent Application Publication Apr. 1, 2004 Sheet 1 of 13 US 2004/0063677 A1 Fig. 1. 7O 60 w 50 40 O) S 3O 2O O O Liposomes Naproxen Oley Oley Oley ether ester amide Patent Application Publication Apr. 1, 2004 Sheet 2 of 13 US 2004/0063677 A1 Fig. 2. 18 16 14 12 Liposomes Naproxen Oley Oley Oley ether ester amide Patent Application Publication Apr. 1, 2004 Sheet 3 of 13 US 2004/0063677 A1 Fig. 3. 550 500 450 400 350 g 3OO 250 200 150 1 OO 50 Ol Liposomes Naproxen Olevt Oleyester amideOley Patent Application Publication Apr. 1, 2004 Sheet 4 of 13 US 2004/0063677 A1 Fig. 4. 2OO R 100 Liposomes Naproxen Oleyi Oley Oley ether ester amide Patent Application Publication Apr. 1, 2004 Sheet 5 of 13 US 2004/0063677 A1 Fig. 5. 3 O 2 5 121 OO5 O 6 a- 24 48 72 Hours post injection OControl Prednisolone Prednisolone-elaidate Patent Application Publication Apr. 1, 2004 Sheet 6 of 13 US 2004/0063677 A1 O O. O. O. O. O. O. O. O. O O. O. O. O. O. O. O O O. O. O. O. O. O. O. O LO O O O O O LO v CO CO CN CN v u/\u) OoueoSeugunueuo Patent Application Publication Apr. 1, 2004 Sheet 7 of 13 US 2004/0063677 A1 Fig. 7. 22O5 1 5 1 O O 6 2 2. 48 t Hours post treatment OControl Prednisolone Prednisolone-elaidate Patent Application Publication Apr. 1, 2004 Sheet 8 of 13 US 2004/0063677 A1 Fig. 8. 25 12 5O 1 O O 6 2 24 48 72 Hours post treatment Control Prednisolone Prednisolone-elaidate US 2004/0063677 A1 uequunNSI?00goOL)dxa(9 IIIIIIIIIIIIIIIIIIIIIIIIIIIIIII|, Patent Application Publication Apr. 1, 2004 Sheet 10 of 13 US 2004/0063677 A1 Patent Application Publication Apr. 1, 2004 Sheet 11 of 13 US 2004/0063677 A1 Fig. 11. 250 200 150 O O 5 O O O 20 40 60 80 OO 120 Time (minutes) -0-DOX - P --DOX - CAT - P -O-DOX - R -O-DOx - CAT - R Patent Application Publication Apr. 1, 2004 Sheet 12 of 13 US 2004/0063677 A1 Fig. 12. 4OO 12OO 2 1000 2. s 800 c g 600 c) O 9. 9 400 200 2 O O 2O 40 60 80 100 120 Time (minutes) -- Daunorubicine-elaidic-amide CEM -- Daunorubicine-elaidate-amide VLB Daunorubicine-oleic-carbamate CEM -- Daunorubicine-oleyl-carbamate VLB Patent Application Publication Apr. 1, 2004 Sheet 13 of 13 US 2004/0063677 A1 Fig. 13. 6OOO 5OOO 4000 3 O O O 2OOO OOO O 2O 40 60 8O 1 OO 120 Time (minutes) -- Daunorubicine CEM --Daunorubicine VLB US 2004/OO63677 A1 Apr. 1, 2004 METHODS OF TREATING DSORDERS USING biological and therapeutic activity as anti-Viral agents as LIPOPHILIC DERIVATIVES ara-cytidine itself. The compound 2,2'-anhydro-5'-O-oleyl ara-cytidine is specially mentioned. I. FIELD OF THE INVENTION 0008 EP-A-56265 discloses esters of arabino-furanosyl 0001. This invention relates to biologically active com thymine (Ara T) with saturated acids having 1-17 C-atoms. pounds, and it is concerned with providing by means of 0009 From PCT/WO90/00555 there are known lipid chemical derivatisation, a technique whereby the behaviour derivatives linked, especially through a phosphate group, to of many biologically active compounds, Such as drugs and the 5'-position of the pentose group of a nucleoside. The agricultural chemicals, may be favourably modified. purpose of this derivatisation is to make the nucleosides more lipophilic So that they could be included into lipo II. BACKGROUND OF THE INVENTION Somes, which are preferentially taken up by macrophages 0002 There is a great interest in the medical community and monocytes, cells which are found to harbour the HIV to investigate and improve the transport efficiency of drugs Virus. It is Stated that a targeting effect is thereby achieved. to the site of action in the patient. The work has mainly been 0010. The anti-viral and anti-cancer activities of nucleo focused on resorption of a drug from the intestine to the Side analogues are directly linked to intra-cellular phospho blood Stream, although transport across other biological rylation of the administered drug. This biochemical trans barriers often plays an important role in obtaining the formation is normally effectuated by viral and/or cellular necessary therapeutic effect in the treatment of many dis enzymes. To improve the effect WO96/25421 discloses eases like cancer, infections, inflammations, CNS disorders phospholipid derivatives of nucleosides with relatively short etc. The transport acroSS the cell membrane is often a main impediment to achieve optimal effect with a therapeutic chain (C or less) Saturated or unsaturated fatty acids. compound. 0011. The art has also sought to improve the character istics of other classes of pharmaceutical Substance through 0.003 Over the last decades drug resistance in the treat ment of malignant and infectious diseases has become derivatisation with fatty acids. increasingly prevalent and is now regarded as a Serious 0012 For example, WO96/22303 teaches that the clinical problem. The development of drug resistance can be pharmokinetic profile and mode of delivery of Several due to a number of mechanisms, but quite often relates to a different categories of therapeutic compounds (corticoster triggering of the normal mechanisms whereby microorgan ones, opioids and opioid antagonists, anti-Viral nucleosides, isms and cells clear toxic compounds to Subtoxic levels. One cyclosporins and related cyclopeptides, folate antagonists, example is the development of multi-drug resistance (MDR) catecholamine precursors and catecholamines and alkylating in cancer cells. In this case MDR frequently relates to a agents containing a carboxylic acid group) can be altered by cellular membrane protein pump by which the cells achieve conjugating them to one to three acyl derivatives of fatty a very efficient efflux of toxic compounds. In a clinical acids through the use of a linker/Spacer group which Situation, i.e. the treatment of a tumour with a cytostatic includes a tromethamine or ethanolamine derivative. Palm drug, cells with the most potent protein pump can prefer itic acid is the preferred fatty acid. entially Survive, and these cells may proliferate to a new 0013 Lipophilic pro drugs of several NSAIDs are known tumour which may be resistant to treatment with a variety of from H. Bundgaard et al (International Journal of Pharma different drugs. Similar mechanisms of action may be ceutics, 43 101-110 1988) and V. R. Shanbhag et al (Journal responsible for the lack of effect Seen in other therapeutic of Pharmaceutical Sciences, 149 Vol. 81, No. 2, February areas, for instance with anti-malarial drugs. 1992). In addition to the pro drug aspect, reduced GI 0004 Several techniques to try to circumvent resistance irritation is reported. EP-A-0195570 suggests that the mechanisms in the clinic are known. For example, the administration of gamma-linolenic and dihomo-gamma-li co-administration of a Ca" channel blocker Such as Vera nolenic acid in conjunction with NSAIDs reduces the side pamil or an immunomodulating agent like cycloSporin, have effects shown by the NSAIDs when taken on a continuing been tried out. However, no significant improvements have basis. been reported So far. 0014 U.S. Pat. No. 5,284.876 teaches the use of docosa 0005 There have been several proposals in the literature hexaenoic acid amides of dopamine as per oral pro drugs in for improving the therapeutic index, bioavailability, mem the treatment of CNS disorders. brane passage, organ targeting, etc of therapeutic com 0015 Physical mixtures containing fatty acids/fatty acid pounds by combining the compounds with fatty acids So as derivatives used as So-called penetration enhancers both to form either chemically coupled derivatives or physical with dermal and per oral administration are known from mixtures. PCT/US94/02880 and PCT/SE96/00122. 0006 Thus, for example, EP-A-393920 discloses that 0016 AS indicated, many of these prior proposals con anti-viral nucleosides and nucleoside analogues which are cern fatty acid derivatives of anti-Viral nucleosides and derivatised with long chain (C upwards) acyl groups have nucleoside analogues.
Load more

Recommended publications
  • Health Reports for Mutual Recognition of Medical Prescriptions: State of Play
    The information and views set out in this report are those of the author(s) and do not necessarily reflect the official opinion of the European Union. Neither the European Union institutions and bodies nor any person acting on their behalf may be held responsible for the use which may be made of the information contained therein. Executive Agency for Health and Consumers Health Reports for Mutual Recognition of Medical Prescriptions: State of Play 24 January 2012 Final Report Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Acknowledgements Matrix Insight Ltd would like to thank everyone who has contributed to this research. We are especially grateful to the following institutions for their support throughout the study: the Pharmaceutical Group of the European Union (PGEU) including their national member associations in Denmark, France, Germany, Greece, the Netherlands, Poland and the United Kingdom; the European Medical Association (EMANET); the Observatoire Social Européen (OSE); and The Netherlands Institute for Health Service Research (NIVEL). For questions about the report, please contact Dr Gabriele Birnberg ([email protected] ). Matrix Insight | 24 January 2012 2 Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Executive Summary This study has been carried out in the context of Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross- border healthcare (CBHC). The CBHC Directive stipulates that the European Commission shall adopt measures to facilitate the recognition of prescriptions issued in another Member State (Article 11). At the time of submission of this report, the European Commission was preparing an impact assessment with regards to these measures, designed to help implement Article 11.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Elif Fatma Sen BW.Indd
    Use and Safety of Respiratory Medicines in Children E. F. Şen EEliflif FFatmaatma SSenen BBW.inddW.indd 1 003-01-113-01-11 115:175:17 The work presented in this thesis was conducted at the Department of Medical Informatics of the Erasmus University Medical Center, Rotterdam. The research reported in thesis was funded by the European Community’s 6th Framework Programme. Project number LSHB-CT-2005-005216: TEDDY: Task force in Europe for Drug Development for the Young. The contributions of the participating primary care physicians in the IPCI, Pedianet and IMS-DA project are greatly acknowledged. Financial support for printing this thesis was kindly provided by the department of Medical Informatics – Integrated Primary Care Information (IPCI) project of the Erasmus University Medi- cal Center; and by the J.E. Jurriaanse Stichting in Rotterdam. Cover: Optima Grafi sche Communicatie Printed by: Optima Grafi sche Communicatie Elif Fatma Şen Use and Safety of Respiratory medicines in Children ISBN: 978-94-6169-003-6 © E.F. Şen, Rotterdam, the Netherlands, 2011. All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without prior written permission of the holder of the copyright. EEliflif FFatmaatma SSenen BBW.inddW.indd 2 003-01-113-01-11 115:175:17 Use and Safety of Respiratory Medicines in Children Het gebruik en de bijwerkingen van respiratoire medicijnen in kinderen Proefschrift Ter verkrijging van de graad van doctor aan de Erasmus Universiteit Rotterdam op gezag van de rector magnifi cus Prof.dr.
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2003/0068365A1 Suvanprakorn Et Al
    US 2003.0068365A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0068365A1 Suvanprakorn et al. (43) Pub. Date: Apr. 10, 2003 (54) COMPOSITIONS AND METHODS FOR Related U.S. Application Data ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME BEADS (60) Provisional application No. 60/327,643, filed on Oct. 5, 2001. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); Tanusin Ploysangam, Bangkok (TH); Publication Classification Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok (51) Int. Cl." .......................... A61K 9/127; A61K 35/78 (TH); Nardo Zaias, Miami Beach, FL (52) U.S. Cl. ............................................ 424/450; 424/725 (US) (57) ABSTRACT Correspondence Address: Law Office of Eric G. Masamori Compositions and methods for administration of active 6520 Ridgewood Drive agents encapsulated within liposome beads to enable a wider Castro Valley, CA 94.552 (US) range of delivery vehicles, to provide longer product shelf life, to allow multiple active agents within the composition, (21) Appl. No.: 10/264,205 to allow the controlled use of the active agents, to provide protected and designable release features and to provide (22) Filed: Oct. 3, 2002 Visual inspection for damage and inconsistency. US 2003/0068365A1 Apr. 10, 2003 COMPOSITIONS AND METHODS FOR toxic degradation of the products, leakage of the drug from ADMINISTRATION OF ACTIVE AGENTS USING the liposome and the modifications of the Size and morphol LPOSOME BEADS ogy of the phospholipid liposome vesicles through aggre gation and fusion. Liposome vesicles are known to be CROSS REFERENCE TO OTHER thermodynamically relatively unstable at room temperature APPLICATIONS and can Spontaneously fuse into larger, leSS Stable altered liposome forms.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • Council of Europe Committee of Ministers (Partial
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (82) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 2 June 1982 at the 348th meeting of the Ministers' Deputies and superseding Resolution AP (77) 1) AND APPENDIX containing the list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 31 October 1982 RESOLUTION AP (82) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION 1 (Adopted by the Committee of Ministers on 2 June 1982 at the 348th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands, the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969 and 5 May 1964, respectively, Considering that, under the terms of its Statute, the aim of the Council of Europe is to achieve a greater unity between its Members for the purpose of safeguarding and realising the ideals and principles which are their common heritage and facilitating their economic and social progress; Having regard to the
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]